News Headline Summary
Bristol Myers (BMY) says US patent on Hepatitis B drug Baraclude invalidated by Delaware federal court
- Co. loses patent challenge from generic drug maker Teva.
- In immediate reaction, Co. shares are unmoved, trades at USD 36.83.
14:34, 12 Feb 2013 -
Subscribe Now to RANsquawk
Click here for a 1 week free trial
RANsquawk provides audio news and commentary for over 15,000
professional traders and brokers worldwide. Services include:
Real-time audio coverage from 0630 to 2130 London time
Teams of analysts covering equities, fixed income, FX and energy markets
Real-time scrolling news service
Daily and weekly pre-market research and calendars
Intra-day market update videos
Daily technical analysis